News Briefing channel feed – Endpoints News

News Briefing channel feed

Ionis widens eplontersen agreement with AstraZeneca; Inozyme looks to get $60M in public offering

Last year

Bristol Myers invests $35M into Immatics; FibroGen names new CEO

Last year

Quince buys a rare disease biotech; Heron reduces headcount

Last year

BioNTech inks cancer deal with Chinese biotech; Eikon, CASI buy Cleave Therapeutics’ assets

Last year

Ginkgo Bioworks handed a DARPA manufacturing contract; Merck hits a primary endpoint for Keytruda in first-line cervical cancer

Last year

Aridis to delist from Nasdaq; Bicycle closes $200M+ offering

Last year

Travere inks bile acid divestiture; Madrigal completes NASH approval request

Last year

Iovance closes $172.5M offering; Veklury approved for Covid-19 patients with severe renal disease

Last year

Bicycle rides to $200M payday, while lung disease biotech raises $80M

Last year

Bristol Myers touts PhIII Opdivo win in urothelial carcinoma; Liminal BioSciences goes private

Last year

Bristol Myers reinforces neuroscience deals; Iovance prices $150M public offering

Last year

The $2.7B Precision/Eli Lilly deal gets modified; Abeona closes $25M direct offering

Last year

UK medical research group reveals £100M rare diseases program; Allarity announces $11M offering

Last year

Lilly to buy European ADC biotech; AbbVie ends SHP2 work with Jacobio

Last year

Hong Kong SPAC nixes diagnostics merger; Clay Siegall will run a public biotech again

Last year

Sutro inks $390M royalty financing deal with Blackstone; Clinical hold on Pharvaris' HAE drug lifted

Last year

Two biotechs launch public offerings; Vaxxinity shares safety data on its Parkinson's vaccine

Last year

Bluebird gets PDUFA date for lovo-cel; FDA lifts hold on DiaMedica stroke trial

Last year

LAVA Therapeutics winds down bispecific trial; Blue Water buys six marketed drugs for $8.5M

Last year

Seagen touts PhII data for Adcetris/Opdivo combo; A-Alpha partners with Gilead on HIV

Last year

FDA sets action date for Phathom after trace carcinogens led to CRL, grants AstraZeneca priority review

Last year

Mozart Therapeutics secures $25M expansion to Series A; LianBio unveils PhIIa data for gastric cancer treatment

Last year

Italian AAV biotech closes $65M Series A; GSK's Jemperli nabs priority review in endometrial cancer

Last year

Bayer buys license to Cedilla preclinical cancer program; MEI Pharma says no to unsolicited offer

Last year

First page Previous page 15 16 171819 20 21 Next page Last page